Ensoma
Ensoma is a privately held, clinical-stage genomic medicines company developing in vivo hematopoietic stem cell (HSC) engineering. Its platform pairs an off-the-shelf in vivo delivery system built on high-capacity virus-like particles that preferentially bind HSCs with a gene engineering toolkit spanning base editing and high-efficiency gene integration, carrying payloads of roughly 35 kilobases so that changes from single-base edits through multi-gene insertions can be made without ex vivo cell collection, manipulation, or transplant conditioning. The company is pursuing programs across genetic disease, immune disorders, and oncology, including EN-374 for X-linked chronic granulomatous disease, and is backed by 5AM Ventures, F-Prime Capital, RTW Investments, Alexandria Venture Investments, Cormorant Asset Management, and the Bill & Melinda Gates Foundation. Enrichment found no public developer API, developer portal, SDK, OpenAPI/GraphQL/AsyncAPI contract, MCP server, or agent card — this is a therapeutics R&D company, not an API provider. Its only public machine-readable output is open-source computational genomics and sequencing-pipeline code published under its GitHub organization.
Ensoma is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Genomic Medicine, Gene Therapy, and Cell Therapy.
Ensoma’s developer surface includes product news and 13 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Build 1
SDKs, sample code, and the tooling you integrate with
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 5
The organization behind the API
Other 3
Properties that don't map to a standard resource type